Product Pipeline

/Product Pipeline
Product Pipeline 2018-08-14T11:55:57+00:00

Immuno-oncology targets

TARGET NAME DISEASE INDICATIONS CURRENT STATUS PROJECTION
ZM008

*New target. Functions through NK cell based therapy

Germinal B cell lymphoma, glioma, hepatocellular carcinoma, prostate cancer In-vivo study completed Preclinical study – 2018

Ph I study – 2019

ZM012

mAb target. Functions through tumour associated antigen/NK cell receptor

Lymphoma and other Undisclosed indications Unique Clone identification in process Lead molecule  – September, 2018
ZM014

mAb target. Functions through tumour NK cell receptor

Lymphoma Unique Clone identification in process Lead molecule  – September, 2018

2

Molecules for NK cell and cell targets under development

Future targets of interest

T Reg Cells

Novel Targets

Academic collaboration in the US